无出血风险患者影像引导活检前血液学筛查的效用低
该研究回顾2007-2016年单中心3864例影像引导经皮穿刺活检,评估无凝血障碍易感条件患者活检前INR和血小板计数异常的 prevalence。结果显示此类患者INR>1.5仅0.8%、>1.8仅0.1%,血小板≤50×10^9/L仅0.4%;取消活检者异常率亦低。作者认为无已知出血风险患者异常发现罕见,取消该检测可节省成本和时间。
要点
- 无出血风险患者活检前INR>1.5者仅0.8%,INR>1.8者仅0.1%
- 无出血风险患者血小板≤50×10^9/L者仅0.4%
- 无易感条件患者取消活检者INR>1.5者0.6%、>1.8者0.0%、血小板≤50×10^9/L者0.1%
核心结论
- 无已知出血风险患者行影像引导经皮穿刺活检前,发现INR或血小板计数异常罕见。
- 取消无易感条件患者的该检测可能为医患节省成本和时间。
研究设计与样本
- 单中心回顾性电子病历审查,纳入2007-2016年放射科计划活检患者。
- 记录人口学数据、出血易感病史及活检前30天内INR和血小板值。
- 按已执行活检与取消活检分层分析。
- 10年间执行经皮活检3864例,取消活检6371例。
关键影像表现/征象
- 约半数活检(48.2%)在无易感条件患者中执行。
- 无易感条件患者中,INR>1.5者0.8%、INR>1.8者0.1%、血小板≤50×10^9/L者0.4%。
- 无易感条件患者取消活检者中,INR>1.5者0.6%、INR>1.8者0.0%、血小板≤50×10^9/L者0.1%。
诊断标准与关键数值
- 无已知易感条件患者中,INR>1.5占0.8%、INR>1.8占0.1%、血小板≤50×10^9/L占0.4%。
- 无已知易感条件患者取消活检者中,INR>1.5占0.6%、INR>1.8占0.0%、血小板≤50×10^9/L占0.1%。
临床应用与阅片要点
- 对于无已知出血风险拟行影像引导经皮穿刺活检的患者,术前INR或血小板异常罕见。
- 取消无易感条件患者的术前血液学检测可能节省成本和时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. This study evaluates the prevalence of an abnormal international normalized ratio (INR) and platelet count before image-guided percutaneous needle biopsies over a 10-year period, comparing data from patients with and those without known conditions predisposing to coagulopathy. MATERIALS AND METHODS. A review of electronic medical records identified patients who were scheduled for a biopsy in a single institution's radiology department for the period of 2007-2016. The following information was recorded: demographic data, patient history of conditions that predispose to bleeding (e.g., liver disease, anticoagulant therapy, history of coagulopathy), and INR and platelet values within 30 days before biopsy. Data were stratified by biopsies that were performed versus those that were cancelled. RESULTS. Over 10 years, 3864 percutaneous biopsies were performed, and 6371 were cancelled. Approximately half of the biopsies (48.2%) were performed in patients without a predisposing condition; of those patients, 0.8% and 0.1% had an INR greater than 1.5 and greater than 1.8, respectively, and 0.4% had a platelet count of 50,000/μL or less (≤ 50 × 109/L). In patients with no known predisposing condition, 0.6% and 0.0% of biopsies cancelled were in patients who had an INR greater than 1.5 and greater than 1.8, respectively, and 0.1% of biopsies cancelled were in patients who had a platelet count of 50,000/μL or less. Ordering prebiopsy testing of patients with no predisposing conditions for the 1864 percutaneous biopsies performed over the 10-year study period resulted in more than $850,000 in laboratory-related health care costs. Our results suggest that the cost of identifying one abnormal INR is nearly $700,000. CONCLUSION. For patients without any known bleeding risks who are scheduled to undergo image-guided percutaneous biopsies, identifying an abnormal INR or abnormal platelet count is rare. Eliminating this testing in patients without predisposing conditions has the potential to create savings in costs and time for both physicians and patients.
引用
- Matsumoto MM, Altman A, Jothishankar B, et al. Low Utility of Screening Hematologic Testing for Image-Guided Biopsies in Patients Without Bleeding Risks. AJR Am J Roentgenol. 2020. PMID: 32901565. doi:10.2214/AJR.19.22414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。